Potential small‐molecule drugs as available weapons to fight novel coronavirus (2019‐nCoV): A review

Since the new coronavirus known as 2019‐nCoV (severe acute respiratory syndrome coronavirus 2, SARS‐CoV‐2) has widely spread in Wuhan, China, with severe pneumonia, scientists and physicians have made remarkable efforts to use various options such as monoclonal antibodies, peptides, vaccines, small‐...

Full description

Saved in:
Bibliographic Details
Published in:Cell Biochemistry and Function 2021-01, Vol.39 (1), p.4-9
Main Authors: Rahimkhoei, Vahid, Jabbari, Nassrollah, Nourani, Aynaz, Sharifi, Sina, Akbari, Ali
Format: Article
Language:English
Subjects:
2019‐nCoV
Antiviral Agents - therapeutic use
China - epidemiology
Coronaviridae
Coronaviruses
COVID-19
COVID-19 - epidemiology
COVID-19 - metabolism
COVID-19 Drug Treatment
Drug development
Drugs
Humans
infection
Infections
Interferon
Monoclonal antibodies
Peptides
Physicians
Review
SARS-CoV-2 - metabolism
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
small‐molecule drugs
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since the new coronavirus known as 2019‐nCoV (severe acute respiratory syndrome coronavirus 2, SARS‐CoV‐2) has widely spread in Wuhan, China, with severe pneumonia, scientists and physicians have made remarkable efforts to use various options such as monoclonal antibodies, peptides, vaccines, small‐molecule drugs and interferon therapies to control, prevent or treatment infections of 2019‐nCoV. However, no vaccine or drug has yet been confirmed to completely treat 2019‐nCoV. In this review, we focus on the use of potential available small‐molecule drug candidates for treating infections caused by 2019‐nCoV.
ISSN:0263-6484
1099-0844
DOI:10.1002/cbf.3576